Do we have to anticoagulate patients with cerebral venous thrombosis?

G. Fehér, Zsolt Illes, David Hargroves, S. Komoly

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5% and 76.4% of the patients had favorable outcome; 85.5% received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1% received long-term anticoagulation. Recurent CVT occured in 3.7% and other thrombotic event occured in 5.4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

Original languageEnglish
Pages (from-to)369-373
Number of pages5
JournalInternational Angiology
Volume35
Issue number4
Publication statusPublished - Aug 1 2016

Fingerprint

Intracranial Thrombosis
Venous Thrombosis
Recurrence
Low Molecular Weight Heparin
Venous Thromboembolism
Multicenter Studies

Keywords

  • Follow-up studies
  • Recurrence
  • Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Do we have to anticoagulate patients with cerebral venous thrombosis? / Fehér, G.; Illes, Zsolt; Hargroves, David; Komoly, S.

In: International Angiology, Vol. 35, No. 4, 01.08.2016, p. 369-373.

Research output: Contribution to journalReview article

Fehér, G. ; Illes, Zsolt ; Hargroves, David ; Komoly, S. / Do we have to anticoagulate patients with cerebral venous thrombosis?. In: International Angiology. 2016 ; Vol. 35, No. 4. pp. 369-373.
@article{af1493e867f548bbab0d0b021139d3e0,
title = "Do we have to anticoagulate patients with cerebral venous thrombosis?",
abstract = "Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5{\%} and 76.4{\%} of the patients had favorable outcome; 85.5{\%} received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1{\%} received long-term anticoagulation. Recurent CVT occured in 3.7{\%} and other thrombotic event occured in 5.4{\%}. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.",
keywords = "Follow-up studies, Recurrence, Therapeutics",
author = "G. Feh{\'e}r and Zsolt Illes and David Hargroves and S. Komoly",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "35",
pages = "369--373",
journal = "International Angiology",
issn = "0392-9590",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Do we have to anticoagulate patients with cerebral venous thrombosis?

AU - Fehér, G.

AU - Illes, Zsolt

AU - Hargroves, David

AU - Komoly, S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5% and 76.4% of the patients had favorable outcome; 85.5% received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1% received long-term anticoagulation. Recurent CVT occured in 3.7% and other thrombotic event occured in 5.4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

AB - Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5% and 76.4% of the patients had favorable outcome; 85.5% received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1% received long-term anticoagulation. Recurent CVT occured in 3.7% and other thrombotic event occured in 5.4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.

KW - Follow-up studies

KW - Recurrence

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84978438079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978438079&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84978438079

VL - 35

SP - 369

EP - 373

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 4

ER -